M1FG
KYMR icon

Mach-1 Financial Group’s Kymera Therapeutics KYMR Stock Holding History

Mach-1 Financial Group’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7,594
Closed -$331K – 339
2025
Q2 		$331K Buy
+7,594
New +$261K 0.1% 178

Other funds holding KYMR

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Mach-1 Financial Group's KYMR Position: Q3 2025 in Review

Mach-1 Financial Group sold out of Kymera Therapeutics (KYMR) in Q3 2025, closing a stake of 7,594 shares — an estimated $331K sold.

Mach-1 Financial Group first reported a position in KYMR in Q2 2025 and held it in 1 quarter. The position peaked at $331K in Q2 2025. 210 funds tracked by Wall St. Rank hold KYMR as of Q3 2025.

  • Mach-1 Financial Group reported no remaining Kymera Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Mach-1 Financial Group sold 7,594 Kymera Therapeutics shares in Q3 2025, an estimated $331K.
  • Mach-1 Financial Group first reported a position in Kymera Therapeutics in Q2 2025 and held it in 1 quarter.
  • Mach-1 Financial Group's Kymera Therapeutics position peaked at $331K in Q2 2025.
  • 210 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2025.

Based on Mach-1 Financial Group's 13F filing for Q3 2025, filed 12 Nov 2025.